Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bio-Rad Laboratories (BIO)
NYSE:BIO
BIO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$262.12 - $387.99
Previous CloseN/A
Volume33.84K
Average Volume (3M)229.51K
Market Cap
$8.02B
Enterprise Value$9.12B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Apr 24, 2025EPS Estimate
1.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-65.04
Shares Outstanding22,940,805
10 Day Avg. Volume371,977
30 Day Avg. Volume229,508
Standard Deviation0.11
R-Squared0.20
Alpha-0.00522
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.08
Price to Cash Flow (P/CF)12.10
P/FCF Ratio15.00
Enterprise Value/Market Cap1.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.62
Enterprise Value/Ebitda-7.63
Forecast
1Y Price Target
$382.33Price Target Upside33.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Bio-Rad Laboratories News
PremiumCompany Announcements
Bio-Rad Laboratories Updates on Sartorius Investment
PremiumCompany Announcements
Bio-Rad’s Cautious Optimism Amid Earnings Challenges---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe CFO is targeting a significant increase in free cash flow by improving terms with suppliers and employing lean methods to reduce inventories.
Investment OpportunityMonetizing the Sartorius stake could add significant firepower for BIO to accelerate share buybacks, potentially reducing existing float by ~30%.
Strategic ManagementNew operational leaders are emphasizing cost efficiencies and prioritizing high-growth areas.
Bears Say
Corporate GovernanceBIO's relative valuation discount has only widened, suggesting factors like family ownership and dual-class structure may be outweighing the fundamental narrative.
Growth ChallengesBIO's organic growth profile lags behind its Tools/Dx peers.
Working CapitalThe company has more cash tied up in working capital than its peers, with inventory turns significantly down compared to pre-COVID levels.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BIO FAQ
What was Bio-Rad Laboratories’s price range in the past 12 months?
Bio-Rad Laboratories lowest stock price was $262.12 and its highest was $387.99 in the past 12 months.
What is Bio-Rad Laboratories’s market cap?
Bio-Rad Laboratories’s market cap is $8.02B.
When is Bio-Rad Laboratories’s upcoming earnings report date?
Bio-Rad Laboratories’s upcoming earnings report date is Apr 24, 2025 which is in 61 days.
How were Bio-Rad Laboratories’s earnings last quarter?
Bio-Rad Laboratories released its earnings results on Feb 13, 2025. The company reported $2.9 earnings per share for the quarter, beating the consensus estimate of $2.868 by $0.032.
Is Bio-Rad Laboratories overvalued?
According to Wall Street analysts Bio-Rad Laboratories’s price is currently Undervalued.
Does Bio-Rad Laboratories pay dividends?
Bio-Rad Laboratories does not currently pay dividends.
What is Bio-Rad Laboratories’s EPS estimate?
Bio-Rad Laboratories’s EPS estimate is 1.85.
How many shares outstanding does Bio-Rad Laboratories have?
Bio-Rad Laboratories has 22,940,805 shares outstanding.
What happened to Bio-Rad Laboratories’s price movement after its last earnings report?
Bio-Rad Laboratories reported an EPS of $2.9 in its last earnings report, beating expectations of $2.868. Following the earnings report the stock price went down -9.531%.
Which hedge fund is a major shareholder of Bio-Rad Laboratories?
Currently, no hedge funds are holding shares in BIO
---
Bio-Rad Laboratories Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$382.33 (33.85% Upside)
$382.33 (33.85% Upside)
Blogger Sentiment
Bearish
BIO Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 24.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.9%
Last 30 Days ▲ 3.2%
Last 30 Days ▲ 3.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-16.91%
12-Months-Change
Fundamentals
Return on Equity
-24.09%
Trailing 12-Months
Asset Growth
-23.86%
Trailing 12-Months
Company Description
Bio-Rad Laboratories
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the following segments: Life Sciences and Clinical Diagnostics. The Life Science segment develops, manufactures and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialize in quality controls that serve clinical laboratories in the global diagnostics market. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.
---
BIO Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a challenging landscape with significant declines in the Life Science segment and impacts from China policy changes, despite meeting some financial targets and strategic acquisitions. The overall sentiment is cautious with a focus on future improvement.Read More>---
BIO Net sales Breakdown
59.92% Clinical Diagnostics
40.06% Life Science
0.02% Other
---
BIO Stock 12 Month Forecast
Average Price Target
$382.33
▲(33.85% Upside)
Technical Analysis
Best Analysts Covering BIO
1 Year
1 Year Success Rate
10/17 ratings generated profit
1 Year Average Return
+8.72%
reiterated a buy rating 8 days ago
Copying Dan Leonard's trades and holding each position for 1 Year would result in 58.82% of your transactions generating a profit, with an average return of +8.72% per trade.
---